Back to Browse Journals » Biologics: Targets and Therapy » Volume 3

Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs

Authors Manil Kukar, Olga Petryna, Petros Efthimiou

Published 28 September 2009 Volume 2009:3 Pages 443—457


Review by Single-blind

Peer reviewer comments 3

Manil Kukar1, Olga Petryna1, Petros Efthimiou2

1Rheumatology Division, Lincoln Medical and Mental Health Center, New York, NY, USA; 2Lincoln Medical and Mental Health Center, Weill Cornell Medical College, New York, NY, USA

Abstract: Enhanced understanding of the rheumatoid arthritis (RA) pathophysiology and the role of cytokines has enabled the development of innovative biological agents in the last 10 years that target specific parts of the immune response. Failure to achieve adequate response with traditional disease modifying anti-rheumatic drugs (DMARDs) and increasing evidence of ongoing radiographic deterioration of the affected joints despite seemingly clinical response were essential stimuli for the development of biologics. The current and upcoming biological agents are primarily aimed at neutralizing circulating and cell-bound pro-inflammatory cytokines, interfering in the interaction of antigen-presenting and T-lymphocytes, eliminating circulating B-lymphocytes or by interfering with the intracellular signaling mechanisms of immuno-competent cells that lead to inflammation. These agents have improved the currently available treatments due to greater efficacy, fast action and greater tolerability. However, use of these agents has also been associated with significant, although rare, adverse events and considerable cost. Therefore, these agents should be used with caution by experienced clinicians. The present work aims to provide a global and updated review of the current and in-development biological DMARDs for the treatment of RA.

Keywords: biological agents, rheumatoid arthritis, immunomodulators, treatment, cytokines

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Consequences of ongoing retrotransposition in mammalian genomes

Maxwell PH

Advances in Genomics and Genetics 2014, 4:129-142

Published Date: 26 September 2014

Magnetic particle imaging: kinetics of the intravascular signal in vivo

Haegele J, Duschka RL, Graeser M, Schaecke C, Panagiotopoulos N, Lüdtke-Buzug K, Buzug TM, Barkhausen J, Vogt FM

International Journal of Nanomedicine 2014, 9:4203-4209

Published Date: 3 September 2014


Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Medical students’ assessment preferences at King Faisal University, Saudi Arabia

Tarek Tawfik Amin, Feroze Kaliyadan, Nouria Saab Al-Muhaidib

Advances in Medical Education and Practice 2011, 2:95-103

Published Date: 10 March 2011

Free radicals in the aqueous humor of patients with glaucoma

Eiki Oshida, Yukihiro Matsumoto, Kiyomi Arai

Clinical Ophthalmology 2010, 4:653-660

Published Date: 21 June 2010

Management of patients with advanced non-small cell lung cancer: role of gefitinib

Vamsidhar Velcheti, Daniel Morgensztern, Ramaswamy Govindan

Biologics: Targets and Therapy 2010, 4:83-90

Published Date: 19 April 2010

A simple method for assessing the strength of evidence for association at the level of the whole gene

David Curtis, Anna E Vine, Jo Knight

Advances and Applications in Bioinformatics and Chemistry 2008, 1:115-120

Published Date: 17 November 2008

Front line treatment of elderly multiple myeloma in the era of novel agents

Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al

Biologics: Targets and Therapy 2009, 3:99-109

Published Date: 30 October 2008